CR20240302A - Receptores de células t que reconocen p53 mutado (divisional exp. 2020-0170) - Google Patents

Receptores de células t que reconocen p53 mutado (divisional exp. 2020-0170)

Info

Publication number
CR20240302A
CR20240302A CR20240302A CR20240302A CR20240302A CR 20240302 A CR20240302 A CR 20240302A CR 20240302 A CR20240302 A CR 20240302A CR 20240302 A CR20240302 A CR 20240302A CR 20240302 A CR20240302 A CR 20240302A
Authority
CR
Costa Rica
Prior art keywords
cell receptors
mammal
methods
receptors recognizing
mutated
Prior art date
Application number
CR20240302A
Other languages
English (en)
Inventor
Drew C Deninger
Steven A Rosenberg
Rami Yoseph
Parisa Malekzadeh
Anna Pasetto
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of CR20240302A publication Critical patent/CR20240302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe un receptor de células T (TCR) aislado o purificado que tiene especificidad antigénica para p53 humano mutado. También se proporcionan polipéptidos y proteínas relacionadas, así como ácidos nucleicos, vectores de expresión recombinante, células hospedadoras, poblaciones de células y composiciones farmacéuticas relacionadas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir cáncer en un mamífero
CR20240302A 2017-09-29 2018-09-17 Receptores de células t que reconocen p53 mutado (divisional exp. 2020-0170) CR20240302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29
PCT/US2018/051285 WO2019067243A1 (en) 2017-09-29 2018-09-17 T CELL RECEPTORS RECOGNIZING P53 MUTE

Publications (1)

Publication Number Publication Date
CR20240302A true CR20240302A (es) 2024-11-07

Family

ID=63714167

Family Applications (4)

Application Number Title Priority Date Filing Date
CR20250153A CR20250153A (es) 2017-09-29 2018-09-17 RECEPTORES DE CÉLULAS T QUE RECONOCEN P53 MUTADO (Divisional Expediente 2020-0170)
CR20240303A CR20240303A (es) 2017-09-29 2018-09-17 Receptores de células t que reconocen p53 mutado (divisional expediente 2020-0170)
CR20240302A CR20240302A (es) 2017-09-29 2018-09-17 Receptores de células t que reconocen p53 mutado (divisional exp. 2020-0170)
CR20200170A CR20200170A (es) 2017-09-29 2018-09-17 Receptores de células t que reconocen p53 mutado

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CR20250153A CR20250153A (es) 2017-09-29 2018-09-17 RECEPTORES DE CÉLULAS T QUE RECONOCEN P53 MUTADO (Divisional Expediente 2020-0170)
CR20240303A CR20240303A (es) 2017-09-29 2018-09-17 Receptores de células t que reconocen p53 mutado (divisional expediente 2020-0170)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20200170A CR20200170A (es) 2017-09-29 2018-09-17 Receptores de células t que reconocen p53 mutado

Country Status (20)

Country Link
US (2) US11939365B2 (es)
EP (2) EP3688027B1 (es)
JP (3) JP7324193B2 (es)
KR (2) KR20250024096A (es)
CN (2) CN111386282B (es)
AU (2) AU2018342246B2 (es)
BR (1) BR112020006012A2 (es)
CA (1) CA3077024A1 (es)
CR (4) CR20250153A (es)
DK (1) DK3688027T3 (es)
EA (1) EA202090757A1 (es)
ES (1) ES3056082T3 (es)
FI (1) FI3688027T3 (es)
IL (1) IL273515B2 (es)
MA (1) MA50651A (es)
MX (4) MX421596B (es)
PL (1) PL3688027T3 (es)
PT (1) PT3688027T (es)
SG (1) SG11202002636PA (es)
WO (1) WO2019067243A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法
AU2020285380A1 (en) * 2019-05-27 2022-01-20 Provincial Health Services Authority Immunotherapy constructs targeting KRAS antigens
WO2020264269A1 (en) * 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
AU2021336399A1 (en) * 2020-09-04 2023-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022212682A2 (en) * 2021-03-31 2022-10-06 The Johns Hopkins University Methods and materials for targeting tumor antigens
EP4334340A1 (en) * 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2023060195A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
CN116063577B (zh) * 2022-11-18 2025-02-07 重庆医科大学 Tcr或其抗原结合片段及其应用
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
EP4750486A2 (en) * 2023-07-25 2026-06-03 Memorial Sloan Kettering Cancer Center T cell receptors targeting tp53 hotspot mutations and uses thereof
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途
WO2025226769A1 (en) * 2024-04-24 2025-10-30 Bluesphere Bio, Inc. T cell receptors targeting minor histocompatibility antigen lrh-1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression
WO2026040998A1 (zh) * 2024-08-20 2026-02-26 上海灵识质源生物技术有限公司 Tp53突变体表位肽和特异性t细胞受体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) * 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
WO2004018619A2 (en) * 2001-06-05 2004-03-04 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
RU2693487C2 (ru) 2013-08-07 2019-07-03 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Пептиды, способные реактивировать мутанты р53
DK3105335T3 (da) * 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
US20170158749A1 (en) * 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
ES2924709T3 (es) * 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
WO2016141169A1 (en) * 2015-03-03 2016-09-09 Caris Mpi, Inc. Molecular profiling for cancer
US10544392B2 (en) * 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2023108150A1 (en) * 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy

Also Published As

Publication number Publication date
MX2020003504A (es) 2020-09-14
CN118955684A (zh) 2024-11-15
IL273515B1 (en) 2025-11-01
US20240270814A1 (en) 2024-08-15
MX421596B (es) 2025-03-14
PT3688027T (pt) 2025-12-16
AU2018342246B2 (en) 2024-08-08
JP7573075B2 (ja) 2024-10-24
PL3688027T3 (pl) 2026-04-07
US11939365B2 (en) 2024-03-26
AU2024227695A1 (en) 2024-12-05
IL273515A (en) 2020-05-31
MX2024005677A (es) 2024-06-11
EP3688027A1 (en) 2020-08-05
JP2023159112A (ja) 2023-10-31
JP7324193B2 (ja) 2023-08-09
JP7814467B2 (ja) 2026-02-16
BR112020006012A2 (pt) 2020-10-06
KR102762272B1 (ko) 2025-02-07
MA50651A (fr) 2020-08-05
CA3077024A1 (en) 2019-04-04
EP4647442A3 (en) 2026-03-04
KR20250024096A (ko) 2025-02-18
CN111386282A (zh) 2020-07-07
AU2018342246A1 (en) 2020-04-16
US20200277352A1 (en) 2020-09-03
CR20240303A (es) 2024-09-04
EA202090757A1 (ru) 2020-08-21
JP2025020145A (ja) 2025-02-12
WO2019067243A1 (en) 2019-04-04
FI3688027T3 (fi) 2025-12-09
EP4647442A2 (en) 2025-11-12
MX2024005678A (es) 2024-06-11
JP2021500010A (ja) 2021-01-07
CR20250153A (es) 2025-06-03
KR20200064110A (ko) 2020-06-05
CR20200170A (es) 2020-11-23
IL273515B2 (en) 2026-03-01
MX2024005676A (es) 2024-06-11
ES3056082T3 (en) 2026-02-18
EP3688027B1 (en) 2025-09-10
DK3688027T3 (da) 2025-12-15
SG11202002636PA (en) 2020-04-29
CN111386282B (zh) 2024-09-06

Similar Documents

Publication Publication Date Title
MX2024005676A (es) Receptores de celulas t que reconocen p53 mutado.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
CY1125601T1 (el) Υποδοχεις anti-kras-g12d κυτταρων τ
MX2017006865A (es) Receptores de células t de kras anti-mutado.
EA202092044A1 (ru) Химерные рецепторы антигена против cd33 и их применения
MX367279B (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
JOP20210186A1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
PH12013500204A1 (en) Polypeptides for treating and/or limiting influenza infection
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
MX378905B (es) Pestivirus.
MX383506B (es) Parvovirus porcino.
BR112019004017A2 (pt) proteínas quiméricas para direcionar dsrna
BR112018073660A2 (pt) anticorpos anti-fator ix pádua